SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan
Wendelin Moser, Mohammed Ahmed Hassan Fahal
1, Elamin Abualas
1, Shahinaz Bedri, Mahgoub Taj Elsir, Mona Fateh El Rahman Omer Mohamed, Abdelhalim Babiker Mahmoud, Amna Ismail Ibrahim Ahmad, Mohammed A. Adam, Sami Altalib, Ola Adil DafaAllah, Salahaldin Abdallah Hmed, Andrew S. Azman, Iza Ciglenecki, Etienne Gignoux, Alan González, Christine Mwongera, and Manuel Albela Miranda
Author affiliations: Médecins Sans Frontières, Geneva, Switzerland (W. Moser, A.S. Azman, I. Ciglenecki, A. González, C. Mwongera, M. Albela Miranda); Médecins Sans Frontières, Khartoum (M.T. Elsir, A.B. Mahmoud, A.I.I. Ahmad, M.A. Adam, S. Altalib, O.A. DafaAllah, S.A. Hmed); Khartoum State Ministry of Health, Khartoum, Sudan (M.AH. Fahal, E. Abualas, S. Bedri, M.T. Elsir, M.F.E.R.O. Mohamed, O.A. DafaAllah); National Public Health Laboratory, Khartoum (E. Abualas, S. Bedri, O.A. DafaAllah); University of Khartoum, Khartoum (A.B. Mahmoud, M.A. Adam, S. Altalib); Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (A.S. Azman); University of Geneva, Geneva (A.S. Azman); Epicentre, Paris, France (E. Gignoux)
Main Article
Table 1
SARS-CoV-2 antibody seroprevalence test results by age group in cross-sectional survey, Omdurman, Sudan*
Age group |
RDT results
|
|
Adjusted results
|
% Positive (95% CI) |
Relative risk (95% CI) |
p value† |
Seroprevalence (95% CI) |
Relative risk (95% CI) |
p value† |
<5 y, = 299 |
18.7 (14.7–23.5) |
0.4 (0.3–0.5) |
<0.001 |
|
29.0 (22.4–36.9) |
0.3 (0.3–0.4) |
<0.001 |
5–19 y, = 786 |
30.6 (27.5–33.9) |
0.6 (0.5–0.7) |
<0.001 |
|
48.5 (43.3–53.9) |
0.6 (0.5–0.6) |
<0.001 |
20–34 y, = 629 |
35.5 (31.8–39.3) |
0.7 (0.6–0.8) |
<0.001 |
|
56.5 (50.5–62.8) |
0.7 (0.6–0.7) |
<0.001 |
35–49 y, = 342 |
39.5 (34.4–44.7) |
0.8 (0.7–0.9) |
0.006 |
|
63.1 (54.8–71.8) |
0.8 (0.7–0.9) |
<0.001 |
>50 y, = 319
|
50.2 (44.7–55.6)
|
Referent
|
|
80.7 (71.7–89.7)
|
Referent
|
Overall, = 2,375 |
34.3 (32.4–36.2) |
|
|
54.6 (51.4–57.8) |
|
Main Article
Page created: March 28, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.